Other equities research analysts also recently issued research reports about the company. Wells Fargo & Co reissued a buy rating on shares of Crispr Therapeutics in a report on Friday, December 6th. Canaccord Genuity increased their price objective on Crispr Therapeutics from $72.00 to $80.00 and gave the company a positive rating in a report on Wednesday, November 20th. Oppenheimer increased their price target on Crispr Therapeutics from $65.00 to $80.00 and gave the company an outperform rating in a research note on Monday, November 25th. Zacks Investment Research cut Crispr Therapeutics from a hold rating to a sell rating in a research note on Monday, September 30th. Finally, TheStreet upgraded Crispr Therapeutics from a d rating to a c rating in a research note on Monday, October 28th. Three analysts have rated the stock with a sell rating, two have given a hold rating and twelve have assigned a buy rating to the company’s stock. The stock currently has an average rating of Buy and an average target price of $71.38.
Shares of NASDAQ CRSP traded up $0.12 during trading hours on Friday, hitting $59.44. The company had a trading volume of 1,391,345 shares, compared to its average volume of 941,091. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06. Crispr Therapeutics has a 1-year low of $28.95 and a 1-year high of $74.00. The firm’s 50 day moving average is $65.98 and its 200-day moving average is $51.14.
Crispr Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Monday, October 28th. The company reported $2.40 EPS for the quarter, beating the consensus estimate of ($0.95) by $3.35. The company had revenue of $211.93 million during the quarter, compared to the consensus estimate of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. On average, equities research analysts anticipate that Crispr Therapeutics will post 0.65 EPS for the current fiscal year.
In related news, President Rodger Novak sold 33,618 shares of the stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the sale, the president now owns 33,618 shares in the company, valued at approximately $2,353,260. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Pablo J. Cagnoni sold 7,500 shares of the stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $55.00, for a total value of $412,500.00. Following the completion of the sale, the director now owns 7,500 shares in the company, valued at approximately $412,500. The disclosure for this sale can be found here. In the last 90 days, insiders sold 56,118 shares of company stock worth $3,620,760. 21.40% of the stock is owned by company insiders.
A number of hedge funds have recently bought and sold shares of CRSP. NEXT Financial Group Inc increased its position in Crispr Therapeutics by 915.0% during the 3rd quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock worth $25,000 after buying an additional 549 shares during the period. Coastal Investment Advisors Inc. bought a new position in Crispr Therapeutics during the 3rd quarter worth $26,000. US Bancorp DE increased its position in Crispr Therapeutics by 553.7% during the 2nd quarter. US Bancorp DE now owns 621 shares of the company’s stock worth $29,000 after buying an additional 526 shares during the period. BSW Wealth Partners bought a new position in Crispr Therapeutics during the 2nd quarter worth $39,000. Finally, BNP Paribas Arbitrage SA bought a new position in Crispr Therapeutics during the 2nd quarter worth $41,000. Hedge funds and other institutional investors own 49.82% of the company’s stock.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Recommended Story: Compound Annual Growth Rate (CAGR)
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.